^
Association details:
| Biomarker: | BCR-ABL1 fusion |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug: | vodobatinib (SCO - 088) (Bcr-abl tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
84 Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy
Published date:
11/03/2022
Excerpt:
This sub-group analysis evaluates efficacy and safety of vodobatinib in CP-CML pts enrolled in the Phase 1 study, according to lines of prior TKIs received....Pts were administered vodobatinib once daily in 28-day cycles….Major molecular responses (MMR) was achieved in 5 (33.3%), 14 (50.0%) and 8 (53.3%) in 2T, 3T and PON, respectively. Of the 20 pts with MMR as best response, 10 (23.6%) achieved molecular response M4 (BCR::ABL1 >0.01% IS)....Vodobatinib demonstrated efficacy and safety in 2T and 3T pts (including pts treated with ponatinib and asciminib) and is well tolerated.
DOI:
https://doi.org/10.1182/blood-2022-166452
Trial ID:
